Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib

Abstract

Janus kinase (JAK) inhibitors, orally or topically administered, are a relatively new therapeutic option for several immune-driven dermatologic diseases (including atopic dermatitis, psoriasis, alopecia areata, and vitiligo). In the future, we may be able to expand its indications with therapy-resistant pyoderma gangrenosum (PG). Because PG is often challenging to treat because of therapy resistance, frequent relapses, and varying results of the sparse (and mostly off-label) treatment options, there is a clear need for additional therapeutic options.

Topics & Concepts